Prevention of adult pneumococcal pneumonia with the 13-valent pneumococcal conjugate vaccine: CAPiTA, the community-acquired pneumonia immunization trial in adults

Human Vaccines and Immunotherapeutics

Volumn 11, Issue 7, 2015, Pages 1825-1827

  Isturiz, Raul ^a   Webber, Chris ^b  

^a Pfizer Vaccines   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Community acquired pneumonia; Pneumococcal conjugate vaccine

Indexed keywords

PLACEBO; PNEUMOCOCCUS VACCINE; 13-VALENT PNEUMOCOCCAL VACCINE; VACCINE;

AGED; ANTIGEN DETECTION; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; INJECTION SITE REACTION; LETTER; MAJOR CLINICAL STUDY; MYALGIA; PNEUMOCOCCAL INFECTION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STREPTOCOCCUS PNEUMONIA; VACCINATION; BIOASSAY; COMMUNITY-ACQUIRED INFECTIONS; IMMUNIZATION; PNEUMONIA, PNEUMOCOCCAL; PRACTICE GUIDELINE; UNITED KINGDOM; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COMMUNITY-ACQUIRED INFECTIONS; DOUBLE-BLIND METHOD; ENDPOINT DETERMINATION; GUIDELINES AS TOPIC; HUMANS; IMMUNIZATION; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; UNITED KINGDOM; VACCINES, CONJUGATE;

EID: 84944458954     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2015.1043502     Document Type: Letter

References (19)

1. Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, van Werkhoven CH, van Deursen AM, Sanders EA, Verheij TJ, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 2015; 372: 1114-25; PMID:25785969; http://dx. doi. org/10. 1056/NEJMoa 1408544
2. Greenberg RN, Gurtman A, Frenck RW, Strout C, Jansen KU, Trammel J, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults 60-64 years of age. Vaccine 2014; 32: 2364-74; PMID:24606865; http://dx. doi. org/10. 1016/j. vaccine. 2014. 02. 002
3. Jackson LA, Gurtman A, Rice K, Pauksens K, Greenberg RN, Jones TR, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine 2013; 31: 3585-93; PMID:23688527; http://dx. doi. org/10. 1016/j. vaccine. 2013. 05. 010
4. Jackson LA, Gurtman A, van Cleeff M, Jansen KU, Jayawardene D, Devlin C, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine 2013; 31: 3577-84; PMID:23688526; http:// dx. doi. org/10. 1016/j. vaccine. 2013. 04. 085
5. Schwarz TF, Flamaing J, Rumke HC, Penzes J, Juergens C, Wenz A, Jayawardene D, Giardina P, Emini EA, Gruber WC, et al. A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥65 years. Vaccine 2011; 29: 5195-202; PMID:21619909; http://dx. doi. org/10. 1016/j. vaccine. 2011. 05. 031
6. Cohen R, Levy C, Bingen E, Koskas M, Nave I, Varon E. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media. Pediatr Infect Dis J 2012; 31: 297-301; PMID:22330166; http://dx. doi. org/ 10. 1097/INF. 0b013e318247ef84
7. Harboe ZB, Dalby T, Weinberger DM, Benfield T, Molbak K, Slotved HC, Suppli CH, Konradsen HB, Valentiner-Branth P. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin Infect Dis 2014; 59: 1066-3; PMID:25034421; http://dx. doi. org/10. 1093/ cid/ciu524
8. Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM, Petit S, Zansky SM, Harrison LH, Reingold A, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis 2015; 15:301-9; [Epub ahead of print]; PMID:25656600; http://dx. doi. org/ 10. 1016/S1473-3099(14)71081-3
9. Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, Reingold A, Thomas A, Schaffner W, Craig AS, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201: 32-41; PMID:19947881; http:// dx. doi. org/10. 1086/648593
10. Bewick T, Sheppard C, Greenwood S, Slack M, Trotter C, George R, Lim WS. Serotype prevalence in adults hospitalised with pneumococcal non-invasive community- acquired pneumonia. Thorax 2012; 67: 540-5; PMID:22374921; http://dx. doi. org/10. 1136/thoraxjnl- 2011-201092
11. Sherwin RL, Gray S, Alexander R, McGovern PC, Graepel J, Pride MW, Purdy J, Paradiso P, File TM, Jr. Distribution of 13-valent pneumococcal conjugate vaccine Streptococcus pneumoniae serotypes in US adults aged >/=50 years with community-acquired pneumonia. J Infect Dis 2013; 208: 1813-20; PMID:24092845; http://dx. doi. org/10. 1093/infdis/ jit506
12. Grijalva CG, Wunderink RG, Williams D, Zhu Y, Balk R, Fakhran S, Courtney M, Anderson E, Qi C, Hicks L, et al. Distribution of pneumococcal serotypes detected through urine analysis among US adults hospitalized with pneumonia after introduction of PCV13. Presented at: 9th International Symposium on Pneumococci and Pneumococcal Diseases; March 9-13, 2014; Hyderabad, India.
13. Payeras A, Villoslada A, Garau M, Salvador MN, Gallegos MC. Evolution of pneumococcal infections in adult patients during a four-year period after vaccination of a pediatric population with 13-valent pneumococcal conjugate vaccine. Int J Infect Dis 2014; 33: 22-7; PMID:25541296; http://dx. doi. org/10. 1016/j. ijid. 2014. 12. 035
14. Tomczyk S, Bennett NM, Stoecker C, Gierke R, Moore MR, Whitney CG, Hadler S, Pilishvili T. Use of 13-valent oneumococcal conjugate vaccine and 23- valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2014; 63: 822-5; PMID:25233284
15. Schmoele-Thoma B, Jackson LA, Greenberg RN, Frenck R. The immunogenicity of Prevnar 13 in immunocompetent older adults with stable underlying medical conditions is comparable to that in healthy older adults. Presented at: IDWeek; October 17-21, 2012; San Diego, CA.
16. Schmoele-Thoma B, Jackson LA, Greenberg RN, Frenck R, Gurtman A, Isturiz R, Sundaraiyer V, Gruber WC, Scott DA. The immunogenicity of PCV13 compared with PPSV23 in immunocompetent older adults with stable at-risk conditions. Presented at: IDWeek; October 8-12, 2014; Philadelphia, PA, USA.
17. Kaplan SL, Barson WJ, Lin PL, Romero JR, Bradley JS, Tan TQ, Hoffman JA, Givner LB, Mason EO, Jr. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2013; 32: 203-7; PMID:23558320; http://dx. doi. org/10. 1097/INF. 0b013e318275614b
18. Lepoutre A, Varon E, Georges S, Dorleans F, Janoir C, Gutmann L, Levy-Bruhl D. Microbiologists of Epibac, ORP Networks. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012. Vaccine 2015; 33: 359-66; PMID:25448105; http:// dx. doi. org/10. 1016/j. vaccine. 2014. 11. 011
19. Steens A, Bergsaker MA, Aaberge IS, Ronning K, Vestrheim DF. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. Vaccine 2013; 31: 6232-8; PMID:24176490; http://dx. doi. org/10. 1016/j. vaccine. 2013. 10. 032